NCT00077727View on ClinicalTrials.gov

A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.

PHASE3CompletedINTERVENTIONAL

Enrollment

107

Participants

Timeline

Start Date

March 31, 2003

Study Completion Date

February 28, 2005

Conditions

Schizophrenia

Interventions

DRUG

Extended-release galantamine hydrobromide

All Listed Sponsors

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00077727 - A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia. | Biotech Hunter | Biotech Hunter